0001209191-17-046030.txt : 20170721 0001209191-17-046030.hdr.sgml : 20170721 20170721200900 ACCESSION NUMBER: 0001209191-17-046030 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170719 FILED AS OF DATE: 20170721 DATE AS OF CHANGE: 20170721 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SMITH IAN F CENTRAL INDEX KEY: 0001197032 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 17977417 MAIL ADDRESS: STREET 1: C/O ACORDA THERAPEUTICS, INC. STREET 2: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-07-19 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001197032 SMITH IAN F C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, CFO & COO Common Stock 2017-07-19 4 M 0 25500 96.87 A 151738 D Common Stock 2017-07-19 4 M 0 10775 91.05 A 162513 D Common Stock 2017-07-19 4 M 0 55250 77.31 A 217763 D Common Stock 2017-07-19 4 M 0 31875 83.36 A 249638 D Common Stock 2017-07-19 4 S 0 123400 161.00 D 126238 D Common Stock 2017-07-21 4 S 0 400 157.56 D 125838 D Common Stock 2017-07-21 4 S 0 1829 158.62 D 124009 D Common Stock 2017-07-21 4 S 0 815 159.61 D 123194 D Common Stock 2017-07-21 4 S 0 2000 161.01 D 121194 D Common Stock 2017-07-21 4 S 0 5106 161.71 D 116088 D Common Stock 2017-07-21 4 S 0 200 162.40 D 115888 D Common Stock 5306 I 401k Stock Option (Right to Buy) 96.87 2017-07-19 4 M 0 25500 0.00 D 2024-07-14 Common Stock 25500 8500 D Stock Option (Right to Buy) 91.05 2017-07-19 4 M 0 10775 0.00 D 2026-02-01 Common Stock 10775 23707 D Stock Option (Right to Buy) 77.31 2017-07-19 4 M 0 55250 0.00 D 2024-02-04 Common Stock 55250 12750 D Stock Option (Right to Buy) 83.36 2017-07-19 4 M 0 31875 0.00 D 2023-07-29 Common Stock 31875 2125 D Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $157.56 (range $156.99 to $157.90). Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $158.62 (range $158.11 to $159.09). Open market sales reported on this line occurred at a weighted average price of $159.61 (range $159.16 to $159.90). Open market sales reported on this line occurred at a weighted average price of $161.01 (range $160.28 to $161.24). Open market sales reported on this line occurred at a weighted average price of $161.71 (range $161.28 to $162.20). Open market sales reported on this line occurred at a weighted average price of $162.40 (range $162.39 to $162.40). The option vests in 16 quarterly installments from 7/15/2014. The option vests in 16 quarterly installments from 02/02/2016. The option vests in 16 quarterly installments from 02/05/2014. The option vests in 16 quarterly installments from 07/30/2013. /s/ Omar White, Attorney-in-Fact 2017-07-21